homepage-top-section

The new investigational recombinant factor VIII (FVIII) therapy efanesoctocog alfa has been designed to extend protection from bleeds with once-weekly prophylactic dosing for haemophilia A patients. It is

New investor NexPoint led the financing round, which included participation from existing investors Eshelman Ventures, Bristol Myers Squibb, and Kingdon Capital. A convertible note, which was provided by

The companies are seeking approval for the antibody to treat adult patients with prurigo nodularis, which is a chronic inflammatory skin disease that causes extreme itch and skin

Under the collaboration, the company will use its AI drug discovery platform along with Denali Therapeutics’ expertise across the blood-brain barrier (BBB) and neurodegeneration for identifying therapeutically relevant

Anthracyclines just as doxorubicin are the initial treatment of choice for TNBC. Although doxorubicin has reduced breast cancer mortality significantly, it is linked with a dose-dependent cumulative and

Castle Creek is a portfolio company of Paragon Biosciences, which took part in this preferred stock financing. This financing round saw continued support from Fidelity Management & Research

The financing round saw participation from other new investors Pavilion Capital, Section 32, Invus and LifeSci Venture Partners. All of the Series A investors of Moma including Third

Under the agreement terms, Arvinas will leverage the Gemini Virtual Patient models of GNS to gain better understanding of the biology of the underlying disease. Arvinas will understand

The company will use these funds to expedite IN10018’s clinical trials that are currently underway for several types of cancer in the US as well as China, including